ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
USP5 Stabilizes TGFBR1 to Drive Vascular Smooth Muscle Cell Senescence and Atherosclerosis.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Vascular smooth muscle cell (VSMC) senescence contributes importantly to atherosclerotic plaque progression, yet the upstream mechanisms remain incompletely understood. Here, by integrating single-cell RNA sequencing analysis with human plaque validation, we found that TGFBR1 is enriched in senescent VSMCs in atherosclerotic lesions and correlates with senescence-associated markers. In vivo, VSMC-specific TGFBR1 knockin in Apoe-deficient mice accelerated plaque development and increased VSMC senescence. Mechanistically, we identified the deubiquitinase USP5 as a previously unrecognized stabilizer of TGFBR1. USP5 directly interacted with TGFBR1 and selectively removed K48-linked polyubiquitin chains at lysine 213, thereby preventing proteasomal degradation. Stabilized TGFBR1 suppressed the mitochondrial enzyme IDH2, driving a metabolic shift toward glycolysis that sustained apoptosis resistance in senescent VSMCs. Conversely, VSMC-specific knockdown of USP5 reduced TGFBR1 expression, restored IDH2 expression, attenuated glycolytic remodeling, and mitigated atherosclerosis in vivo. Our findings reveal a USP5-TGFBR1-IDH2 axis in which site-specific deubiquitination at K213 links receptor stability to metabolic remodeling and VSMC senescence, identifying USP5 as a potential therapeutic target for atherosclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.